EZH2 and breast cancer: Using EZH2 mutants with a deletion in the nuclear localization signal and a T367 phosphorylation deficient mutant, we directly demonstrate that cytoplasmic localization and T367 phosphorylation are sufficient for EZH2-mediated breast cancer progression.